{"protocolSection":{"identificationModule":{"nctId":"NCT03187197","orgStudyIdInfo":{"id":"1160-0286"},"organization":{"fullName":"Boehringer Ingelheim","class":"INDUSTRY"},"briefTitle":"Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation","officialTitle":"Patients Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation Impact of Conventional Oral Anticoagulant (OAC) Compared With Novel Oral Anticoagulant (NOAC)"},"statusModule":{"statusVerifiedDate":"2020-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-06-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-06-30","type":"ACTUAL"},"completionDateStruct":{"date":"2019-01-11","type":"ACTUAL"},"studyFirstSubmitDate":"2017-06-13","studyFirstSubmitQcDate":"2017-06-13","studyFirstPostDateStruct":{"date":"2017-06-14","type":"ACTUAL"},"resultsFirstSubmitDate":"2020-01-08","resultsFirstSubmitQcDate":"2020-02-11","resultsFirstPostDateStruct":{"date":"2020-02-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-02-11","lastUpdatePostDateStruct":{"date":"2020-02-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Boehringer Ingelheim","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"To describe the treatment perception from patients with non-valvular atrial fibrillation (NVAF) receiving Pradaxa® or VKA for stroke prevention by using the self-estimation questionnaire of PACT-Q during a 6-month study period."},"conditionsModule":{"conditions":["Atrial Fibrillation"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":1315,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort A","description":"consented patients with NVAF in Taiwan with a previous VKA therapy, followed by switching to Pradaxa®","interventionNames":["Drug: Pradaxa®"]},{"label":"Cohort B","description":"patients being newly diagnosed with NVAF and initiated on Pradaxa®","interventionNames":["Drug: Pradaxa®"]}],"interventions":[{"type":"DRUG","name":"Pradaxa®","description":"Dabigatran etexilate","armGroupLabels":["Cohort A","Cohort B"],"otherNames":["Dabigatran etexilate"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Mean Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second and Last Assessment Compared to Baseline Assessment","description":"The PACT-Q was a self-administered questionnaire which was developed as a means to investigate patients´ satisfaction with anticoagulant treatment and treatment convenience in patients with deep venous thrombosis (DVT), pulmonary embolism (PE) or atrial fibrillation (AF). The PACT-Q2 was composed of three dimensions covering: convenience (11 items), burden of disease and treatment (2 items), and anticoagulant treatment satisfaction (7 items). Items for convenience and for burden of disease and treatment were reversed(reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score (CDS). Items for anticoagulant treatment satisfaction were summed and rescaled on a 0-100 scale to determine the satisfaction dimension score (SDS). High scores were more favorable. The two dimension scores were presented for Baseline, Visit 2 (second assessment) and Visit 3 (last assessment) as mean and standard deviation (SD).","timeFrame":"Baseline, Visit 2 (30-45 days after initiation on Pradaxa®), Visit 3 (150-210 days after initiation on Pradaxa®)."},{"measure":"Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups","description":"The PACT-Q2 was composed of three dimensions covering: convenience (11 items), burden of disease and treatment (2 items), and anticoagulant treatment satisfaction (7 items). The PACT-Q2 was to be administered to patients once treatment was ongoing. Items for convenience and for burden of disease and treatment were reversed (reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score. Items for anticoagulant treatment satisfaction were summed and rescaled on a 0-100 scale to determine the satisfaction dimension score. High scores were more favorable. The two dimension scores were presented for Visit 2 (second assessment) and Visit 3 (last assessment) as mean and standard deviation (SD). Propensity score matching (PSM) method was used to identify matched Pradaxa® and VKA patients. Only the matched patients in each treatment group was summarized and used for comparison.","timeFrame":"Visit 2 (30-45 days after initiation on Pradaxa® or VKA) and Visit 3 (150-210 days after initiation on Pradaxa® or VKA)."}],"secondaryOutcomes":[{"measure":"Mean PACT-Q2 Scores, for Patients in Cohort A, at Last Assessment Compared to Second Assessment","description":"The PACT-Q2 was composed of three dimensions covering: convenience (11 items), burden of disease and treatment (2 items), and anticoagulant treatment satisfaction (7 items). The PACT-Q2 was to be administered to patients once treatment was ongoing. Items for convenience and for burden of disease and treatment were reversed (reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score. Items for anticoagulant treatment satisfaction were summed and rescaled on a 0-100 scale to determine the satisfaction dimension score. High scores were more favorable. The two dimension scores were presented for Visit 2 (second assessment) and Visit 3 (last assessment) as mean and standard deviation (SD).","timeFrame":"Visit 2 (30-45 days after initiation on Pradaxa®) and Visit 3 (150-210 days after initiation on Pradaxa®)."},{"measure":"Description of PACT-Q1 Items for Patients in Cohort B at Baseline","description":"The PACT-Q1 was composed of a single dimension (7 items), covering the expectations of patients regarding their anticoagulant treatment, and was to be administered before treatment initiation. The 7 items were: Q1: How confident are you that your anticoagulant treatment will prevent blood clots? Q2: Do you expect that your anticoagulant treatment will relieve some of the symptoms you experience? Q3: Do you expect that your anticoagulant treatment will cause side effects such as minor bruises or bleeding? Q4: How important is it for you to have an anticoagulant treatment that is easy to take? Q5: How concerned are you about making mistakes when taking your anticoagulant treatment? Q6: How important is it for you to take care of your anticoagulant treatment by yourself? Q7: How concerned are you about how much you pay for your anticoagulant treatment? Responses ranged from 1 (Not at all) to 5 (Extremely/Completely/Very much).","timeFrame":"Baseline"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\nCohort A (patients switched from VKA to Pradaxa)\n\n* Written informed consent prior to participation.\n* Female or male patients ≥ 20 years of age with a diagnosis of non-valvular atrial fibrillation (NVAF).\n* At least 3 months of continuous VKA treatment for stroke prevention prior to baseline assessment.\n* Patients switched to Pradaxa prior to baseline assessment according to the physician's discretion and the Summary of Product Characteristics (SmPCs)/reimbursement criteria.\n\nOR Cohort B (patients newly initiated Pradaxa or VKA)\n\n* Written informed consent prior to participation.\n* Female or male patients ≥ 20 years of age, newly diagnosed with NVAF, and no previous treatment for stroke prevention (no use of any OAC within 1 year prior to enrolment).\n* Patients initiated stroke prevention treatment with Pradaxa or VKA according to the physician's discretion and the SmPCs/reimbursement criteria.\n\nExclusion criteria:\n\n* Contraindication to the use of Pradaxa® or VKA as described in the SmPCs.\n* Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in NVAF.\n* Current participation in any clinical trial of a drug or device.\n* Current participation in an AF-related registry, e.g. the Gloria AF program.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients 20 years of age or older with a diagnosis of non-valvular atrial fibrillation (NVAF).","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"locations":[{"facility":"Chang-Hua Christian Hospital","city":"Changhua","zip":"500","country":"Taiwan","geoPoint":{"lat":24.07327,"lon":120.56276}},{"facility":"Show Chwan Memorial Hospital","city":"Changhua","country":"Taiwan","geoPoint":{"lat":24.07327,"lon":120.56276}},{"facility":"Chia-Yi Christian Hospital","city":"Chia-Yi City","zip":"40705","country":"Taiwan"},{"facility":"Hsinchu MacKay Memorial Hospital","city":"Hsinchu","country":"Taiwan","geoPoint":{"lat":24.80361,"lon":120.96861}},{"facility":"National Taiwan University Hospital-Hsin-Chu Branch","city":"Hsinchu","country":"Taiwan","geoPoint":{"lat":24.80361,"lon":120.96861}},{"facility":"Kaohsiung Medical University Chung-Ho Memorial Hospital","city":"Kaohsiung","zip":"80756","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"E-Da Hospital","city":"Kaohsiung","zip":"824","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"Kaohsiung Chang Gung Memorial Hospital","city":"Kaohsiung","zip":"83301","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"Far Eastern Memorial Hospital","city":"New Taipei City","zip":"220","country":"Taiwan","geoPoint":{"lat":25.01111,"lon":121.44583}},{"facility":"Taipei Medical University-Shuang Ho Hospital","city":"New Taipei City","zip":"235","country":"Taiwan","geoPoint":{"lat":25.01111,"lon":121.44583}},{"facility":"China Medical University Hospital","city":"Taichung","zip":"40447","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Taichung Veterans General Hospital","city":"Taichung","zip":"40705","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"NCKUH","city":"Tainan","zip":"704","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"Chi Mei Medical Center","city":"Tainan","zip":"710","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"Tainan Municipal An-Nan Hospital","city":"Tainan","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"Taipei Medical University Hospital","city":"Taipei City","zip":"110","country":"Taiwan","geoPoint":{"lat":25.04776,"lon":121.53185}},{"facility":"Taipe Veterans General Hospital","city":"Taipei City","zip":"11217","country":"Taiwan","geoPoint":{"lat":25.04776,"lon":121.53185}},{"facility":"National Taiwan University Hospital","city":"Taipei","zip":"10048","country":"Taiwan","geoPoint":{"lat":25.04776,"lon":121.53185}},{"facility":"Mackay Memorial Hospital","city":"Taipei","zip":"10449","country":"Taiwan","geoPoint":{"lat":25.04776,"lon":121.53185}},{"facility":"Tri-Service General Hospital","city":"Taipei","zip":"114","country":"Taiwan","geoPoint":{"lat":25.04776,"lon":121.53185}},{"facility":"Shin Kong International HealthCare Center","city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.04776,"lon":121.53185}},{"facility":"Taipei Municipal Wanfang Hospital","city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.04776,"lon":121.53185}},{"facility":"Chang Gung Memorial Hospital(TaoYuan)","city":"Taoyuan","zip":"330","country":"Taiwan","geoPoint":{"lat":24.95233,"lon":121.20193}},{"facility":"National Taiwan University Hospital Yun-Lin Branch","city":"Yunlin County","zip":"632","country":"Taiwan"}]},"referencesModule":{"references":[{"pmid":"33784265","type":"DERIVED","citation":"Lee CW, Liu ME, Lee TM, Chang RY, Huang CY, Hu YF, Yeh HI. Patient satisfaction with dabigatrean and warfarin for stroke prevention in atrial fibrillation: Taiwan PASSION study. J Chin Med Assoc. 2021 Apr 1;84(4):375-382. doi: 10.1097/JCMA.0000000000000496."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Data was collected from approximately 20 medical centers or regional hospitals in Taiwan where Pradaxa® is taken as the prescription of stroke prophylaxis (or prevention) in Atrial Fibrillation (AF). Data was collected between June 23, 2017 and Jan 11, 2019. 10 enrolled participants were removed due to screening failures before entering the study.","recruitmentDetails":"This non-interventional study enrolled patients in Taiwan with a previous Vitamin K Antagonist (VKA) therapy, followed by switching to Pradaxa® (one of the novel oral anticoagulants (NOACs)) or patients being newly diagnosed with Non-Valvular Atrial Fibrillation (NVAF) and initiated on Pradaxa® or VKA.","groups":[{"id":"FG000","title":"Cohort A","description":"Patients with a diagnosis of NVAF, who were using VKA therapy for at least 3 months for stroke prevention before entering the study and were switched to Pradaxa®, received 110 or 150 milligram (mg) Pradaxa® capsules twice daily."},{"id":"FG001","title":"Cohort B - Pradaxa®","description":"Patients newly diagnosed with NVAF, not previously treated with an anticoagulant for the prevention of stroke and initiated 110 or 150 mg Pradaxa® capsules twice daily."},{"id":"FG002","title":"Cohort B - VKA","description":"Patients newly diagnosed with NVAF, not previously treated with an anticoagulant for the prevention of stroke, and initiated VKA therapy. The choice of VKA and the appropriate dosing was at the discretion of the physician."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","comment":"Started are Enrolled","achievements":[{"groupId":"FG000","numSubjects":"153"},{"groupId":"FG001","numSubjects":"1097"},{"groupId":"FG002","numSubjects":"55"}]},{"type":"Started (Eligible Participants as FAS)","achievements":[{"groupId":"FG000","numSubjects":"139"},{"groupId":"FG001","numSubjects":"1052"},{"groupId":"FG002","numSubjects":"54"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"107"},{"groupId":"FG001","numSubjects":"704"},{"groupId":"FG002","numSubjects":"32"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"393"},{"groupId":"FG002","numSubjects":"23"}]}],"dropWithdraws":[{"type":"Stopped Pradaxa®/VKA","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"65"},{"groupId":"FG002","numSubjects":"4"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"63"},{"groupId":"FG002","numSubjects":"4"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"7"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"29"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Administrative problem","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Reason not listed","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"54"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Missing","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"32"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Status missing","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"33"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"NA in incl/excl criteria, not analyzed.","reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"45"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Full analysis set (FAS): This set included all subjects who were eligible for study participation.","groups":[{"id":"BG000","title":"Cohort A","description":"Patients with a diagnosis of NVAF, who were using VKA therapy for at least 3 months for stroke prevention before entering the study and were switched to Pradaxa®, received 110 or 150 milligram (mg) Pradaxa® capsules twice daily."},{"id":"BG001","title":"Cohort B - Pradaxa®","description":"Patients newly diagnosed with NVAF, not previously treated with an anticoagulant for the prevention of stroke and initiated 110 or 150 mg Pradaxa® capsules twice daily."},{"id":"BG002","title":"Cohort B - VKA","description":"Patients newly diagnosed with NVAF, not previously treated with an anticoagulant for the prevention of stroke, and initiated VKA therapy. The choice of VKA and the appropriate dosing was at the discretion of the physician."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"1052"},{"groupId":"BG002","value":"54"},{"groupId":"BG003","value":"1245"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68.4","spread":"15.65"},{"groupId":"BG001","value":"71.5","spread":"13.08"},{"groupId":"BG002","value":"67.1","spread":"12.88"},{"groupId":"BG003","value":"71.0","spread":"13.44"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"431"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"505"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"621"},{"groupId":"BG002","value":"37"},{"groupId":"BG003","value":"740"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"1052"},{"groupId":"BG002","value":"54"},{"groupId":"BG003","value":"1245"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"1052"},{"groupId":"BG002","value":"54"},{"groupId":"BG003","value":"1245"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second and Last Assessment Compared to Baseline Assessment","description":"The PACT-Q was a self-administered questionnaire which was developed as a means to investigate patients´ satisfaction with anticoagulant treatment and treatment convenience in patients with deep venous thrombosis (DVT), pulmonary embolism (PE) or atrial fibrillation (AF). The PACT-Q2 was composed of three dimensions covering: convenience (11 items), burden of disease and treatment (2 items), and anticoagulant treatment satisfaction (7 items). Items for convenience and for burden of disease and treatment were reversed(reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score (CDS). Items for anticoagulant treatment satisfaction were summed and rescaled on a 0-100 scale to determine the satisfaction dimension score (SDS). High scores were more favorable. The two dimension scores were presented for Baseline, Visit 2 (second assessment) and Visit 3 (last assessment) as mean and standard deviation (SD).","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units on Scale","timeFrame":"Baseline, Visit 2 (30-45 days after initiation on Pradaxa®), Visit 3 (150-210 days after initiation on Pradaxa®).","groups":[{"id":"OG000","title":"Cohort A","description":"Patients with a diagnosis of NVAF, who were using VKA therapy for at least 3 months for stroke prevention before entering the study and were switched to Pradaxa®, received 110 or 150 milligram (mg) Pradaxa® capsules twice daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"}]}],"classes":[{"title":"Convenience - Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","spread":"13.31"}]}]},{"title":"Convenience - Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":"10.74"}]}]},{"title":"Convenience - Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"107"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","spread":"6.48"}]}]},{"title":"Satisfaction - Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":"11.06"}]}]},{"title":"Satisfaction - Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.1","spread":"13.36"}]}]},{"title":"Satisfaction - Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"107"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.5","spread":"12.41"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Within group comparison of Baseline convenience with that of Visit 2.","nonInferiorityType":"OTHER","pValue":"0.0001","statisticalMethod":"Paired t-test"},{"groupIds":["OG000"],"groupDescription":"Within group comparison of Baseline convenience with that of Visit 3.","nonInferiorityType":"OTHER","pValue":"0.0001","statisticalMethod":"Paired t-test"},{"groupIds":["OG000"],"groupDescription":"Within group comparison of Baseline satisfaction with that of Visit 2.","nonInferiorityType":"OTHER","pValue":"0.0031","statisticalMethod":"Paired t-test"},{"groupIds":["OG000"],"groupDescription":"Within group comparison of Baseline satisfaction with that of Visit 3.","nonInferiorityType":"OTHER","pValue":"0.0001","statisticalMethod":"Paired t-test"}]},{"type":"PRIMARY","title":"Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups","description":"The PACT-Q2 was composed of three dimensions covering: convenience (11 items), burden of disease and treatment (2 items), and anticoagulant treatment satisfaction (7 items). The PACT-Q2 was to be administered to patients once treatment was ongoing. Items for convenience and for burden of disease and treatment were reversed (reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score. Items for anticoagulant treatment satisfaction were summed and rescaled on a 0-100 scale to determine the satisfaction dimension score. High scores were more favorable. The two dimension scores were presented for Visit 2 (second assessment) and Visit 3 (last assessment) as mean and standard deviation (SD). Propensity score matching (PSM) method was used to identify matched Pradaxa® and VKA patients. Only the matched patients in each treatment group was summarized and used for comparison.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units on Scale","timeFrame":"Visit 2 (30-45 days after initiation on Pradaxa® or VKA) and Visit 3 (150-210 days after initiation on Pradaxa® or VKA).","groups":[{"id":"OG000","title":"Cohort B - Pradaxa®","description":"Patients newly diagnosed with NVAF, not previously treated with an anticoagulant for the prevention of stroke and initiated 110 or 150 mg Pradaxa® capsules twice daily."},{"id":"OG001","title":"Cohort B - VKA","description":"Patients newly diagnosed with NVAF, not previously treated with an anticoagulant for the prevention of stroke, and initiated VKA therapy. The choice of VKA and the appropriate dosing was at the discretion of the physician."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1052"},{"groupId":"OG001","value":"54"}]}],"classes":[{"title":"Pre-PSM Convenience - Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"926"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":"9.88"},{"groupId":"OG001","value":"94.3","spread":"5.61"}]}]},{"title":"Pre-PSM Convenience - Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"716"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93.9","spread":"8.41"},{"groupId":"OG001","value":"94.3","spread":"6.35"}]}]},{"title":"Pre-PSM Satisfaction - Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"931"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.1","spread":"11.51"},{"groupId":"OG001","value":"67.3","spread":"9.17"}]}]},{"title":"Pre-PSM Satisfaction - Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"718"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.9","spread":"12.05"},{"groupId":"OG001","value":"75.1","spread":"11.95"}]}]},{"title":"PSM Convenience - Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":"2.18"},{"groupId":"OG001","value":"80.8","spread":"9.79"}]}]},{"title":"PSM Satisfaction - Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":"0.00"},{"groupId":"OG001","value":"64.3","spread":"2.02"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Between group comparison of Visit 2 treatment convenience before PSM.","nonInferiorityType":"OTHER","pValue":"0.7879","statisticalMethod":"t-test, 2 sided"},{"groupIds":["OG000","OG001"],"groupDescription":"Between group comparison of Visit 3 treatment convenience before PSM.","nonInferiorityType":"OTHER","pValue":"0.6110","statisticalMethod":"t-test, 2 sided"},{"groupIds":["OG000","OG001"],"groupDescription":"Between group comparison of Visit 2 treatment satisfaction before PSM.","nonInferiorityType":"OTHER","pValue":"0.0832","statisticalMethod":"t-test, 2 sided"},{"groupIds":["OG000","OG001"],"groupDescription":"Between group comparison of Visit 3 treatment satisfaction before PSM.","nonInferiorityType":"OTHER","pValue":"0.6488","statisticalMethod":"t-test, 2 sided"},{"groupIds":["OG000","OG001"],"groupDescription":"Between group comparison of Visit 2 treatment convenience after PSM.","nonInferiorityType":"OTHER","pValue":"0.1301","statisticalMethod":"Two sample T test"},{"groupIds":["OG000","OG001"],"groupDescription":"Between group comparison of Visit 2 treatment satisfaction after PSM.","nonInferiorityType":"OTHER","pValue":"0.1257","statisticalMethod":"Two sample T test"}]},{"type":"SECONDARY","title":"Mean PACT-Q2 Scores, for Patients in Cohort A, at Last Assessment Compared to Second Assessment","description":"The PACT-Q2 was composed of three dimensions covering: convenience (11 items), burden of disease and treatment (2 items), and anticoagulant treatment satisfaction (7 items). The PACT-Q2 was to be administered to patients once treatment was ongoing. Items for convenience and for burden of disease and treatment were reversed (reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score. Items for anticoagulant treatment satisfaction were summed and rescaled on a 0-100 scale to determine the satisfaction dimension score. High scores were more favorable. The two dimension scores were presented for Visit 2 (second assessment) and Visit 3 (last assessment) as mean and standard deviation (SD).","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units on scale","timeFrame":"Visit 2 (30-45 days after initiation on Pradaxa®) and Visit 3 (150-210 days after initiation on Pradaxa®).","groups":[{"id":"OG000","title":"Cohort A","description":"Patients with a diagnosis of NVAF, who were using VKA therapy for at least 3 months for stroke prevention before entering the study and were switched to Pradaxa®, received 110 or 150 milligram (mg) Pradaxa® capsules twice daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"}]}],"classes":[{"title":"Convenience - Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":"10.74"}]}]},{"title":"Convenience - Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"107"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","spread":"6.48"}]}]},{"title":"Satisfaction - Visit 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.1","spread":"13.36"}]}]},{"title":"Satisfaction - Visit 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"107"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.5","spread":"12.41"}]}]}]},{"type":"SECONDARY","title":"Description of PACT-Q1 Items for Patients in Cohort B at Baseline","description":"The PACT-Q1 was composed of a single dimension (7 items), covering the expectations of patients regarding their anticoagulant treatment, and was to be administered before treatment initiation. The 7 items were: Q1: How confident are you that your anticoagulant treatment will prevent blood clots? Q2: Do you expect that your anticoagulant treatment will relieve some of the symptoms you experience? Q3: Do you expect that your anticoagulant treatment will cause side effects such as minor bruises or bleeding? Q4: How important is it for you to have an anticoagulant treatment that is easy to take? Q5: How concerned are you about making mistakes when taking your anticoagulant treatment? Q6: How important is it for you to take care of your anticoagulant treatment by yourself? Q7: How concerned are you about how much you pay for your anticoagulant treatment? Responses ranged from 1 (Not at all) to 5 (Extremely/Completely/Very much).","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units on scale","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Cohort B - Pradaxa®","description":"Patients newly diagnosed with NVAF, not previously treated with an anticoagulant for the prevention of stroke and initiated 110 or 150 mg Pradaxa® capsules twice daily."},{"id":"OG001","title":"Cohort B - VKA","description":"Patients newly diagnosed with NVAF, not previously treated with an anticoagulant for the prevention of stroke, and initiated VKA therapy. The choice of VKA and the appropriate dosing was at the discretion of the physician."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1052"},{"groupId":"OG001","value":"54"}]}],"classes":[{"title":"Q1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1047"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"1.13"},{"groupId":"OG001","value":"3.0","spread":"0.99"}]}]},{"title":"Q2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1050"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"1.19"},{"groupId":"OG001","value":"3.1","spread":"1.11"}]}]},{"title":"Q3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1049"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"1.09"},{"groupId":"OG001","value":"2.1","spread":"1.00"}]}]},{"title":"Q4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1049"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"1.15"},{"groupId":"OG001","value":"3.7","spread":"1.21"}]}]},{"title":"Q5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1048"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"1.42"},{"groupId":"OG001","value":"2.7","spread":"1.54"}]}]},{"title":"Q6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1049"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"1.12"},{"groupId":"OG001","value":"3.7","spread":"1.09"}]}]},{"title":"Q7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1048"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"1.39"},{"groupId":"OG001","value":"1.9","spread":"1.21"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From signing the informed consent till end of the study; up to 210 days.","description":"For AE reporting the safety set included all enrolled subjects with at least one actual follow-up.\n\nFollowing the updated Guidelines, the cardiologists treat participants using NOAC rather than VKA.\n\nThere is a a major difference of patients included in the various cohorts ; this can be explained by the fact that it is a non-interventional, observational study. Which kind of treatment patients received was based on the investigators' decision according to the patient clinical situation.","eventGroups":[{"id":"EG000","title":"Cohort A","description":"Patients with a diagnosis of NVAF, who were using VKA therapy for at least 3 months for stroke prevention before entering the study and were switched to Pradaxa®, received 110 or 150 milligram (mg) Pradaxa® capsules twice daily.","deathsNumAffected":0,"deathsNumAtRisk":148,"seriousNumAffected":1,"seriousNumAtRisk":148,"otherNumAffected":0,"otherNumAtRisk":148},{"id":"EG001","title":"Cohort B - Pradaxa®","description":"Patients newly diagnosed with NVAF, not previously treated with an anticoagulant for the prevention of stroke and initiated 110 or 150 mg Pradaxa® capsules twice daily.","deathsNumAffected":11,"deathsNumAtRisk":978,"seriousNumAffected":4,"seriousNumAtRisk":978,"otherNumAffected":0,"otherNumAtRisk":978},{"id":"EG002","title":"Cohort B - VKA","description":"Patients newly diagnosed with NVAF, not previously treated with an anticoagulant for the prevention of stroke, and initiated VKA therapy. The choice of VKA and the appropriate dosing was at the discretion of the physician.","deathsNumAffected":0,"deathsNumAtRisk":48,"seriousNumAffected":0,"seriousNumAtRisk":48,"otherNumAffected":0,"otherNumAtRisk":48}],"seriousEvents":[{"term":"Embolic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":978},{"groupId":"EG002","numAffected":0,"numAtRisk":48}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":1,"numAtRisk":978},{"groupId":"EG002","numAffected":0,"numAtRisk":48}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":1,"numAtRisk":978},{"groupId":"EG002","numAffected":0,"numAtRisk":48}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":2,"numAtRisk":978},{"groupId":"EG002","numAffected":0,"numAtRisk":48}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights."},"pointOfContact":{"title":"Boehringer Ingelheim, Call Center","organization":"Boehringer Ingelheim","email":"clintriage.rdg@boehringer-ingelheim.com","phone":"1-800-243-0127"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-02-18","uploadDate":"2020-01-08T02:41","filename":"SAP_000.pdf","size":474704},{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2017-03-15","uploadDate":"2020-01-08T02:41","filename":"Prot_001.pdf","size":926667}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069604","term":"Dabigatran"}],"ancestors":[{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M490","name":"Dabigatran","asFound":"4 hours","relevance":"HIGH"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":true}